Business Context and Reporting Period
This Form 8-K is filed by Lion Biotechnologies, Inc. (not IOVANCE Biotherapeutics, Inc.) on November 4, 2016. The report announces the financial results for the third quarter ended September 30, 2016, and provides an update on recent developments. The detailed financial data is contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1), the content of which is not included in the provided source text.
Material Changes
The filing indicates an update on recent developments alongside the Q3 2016 results. However, the specific nature of material changes versus the prior comparable period is not detailed in the Form 8-K text provided.
Guidance, Outlook, and Risks
The filing references an update on recent developments but does not explicitly state forward-looking guidance, management commentary, specific risks, or contingencies within the body of this report. The filing includes a standard disclaimer that the information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as specifically stated.
Investor Verification Checklist
- Verify the correct registrant name is Lion Biotechnologies, Inc., as the input metadata incorrectly listed IOVANCE Biotherapeutics, Inc.
- Review Exhibit 99.1 (the press release) to obtain actual financial figures for the quarter ended September 30, 2016.
- Confirm the specific details of the "recent developments" mentioned in the press release.
- Note that the financial data in this 8-K is not legally "filed" under Section 18 of the Exchange Act.